Compare Novo Nordisk A/S (NVO) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Summit Therapeutics Inc — how do they compare? Novo Nordisk A/S trades at $38.64 (market cap $165.31B), while Summit Therapeutics Inc trades at $17.59 (market cap $13.71B). The key difference: Novo Nordisk A/S is far larger — about 12.1× Summit Therapeutics Inc's market cap, and Novo Nordisk A/S pays a 4.71% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Summit Therapeutics Inc for 16 Days on average.
| NVO | SMMT | |
|---|---|---|
Market Cap | $165.31B | $13.71B |
Volume | 11,432,838 | 6,173,057 |
Sector | Health | Health |
52-Week High | $63.98 | $26.38 |
52-Week Low | $35.29 | $12.43 |
Typical Hold Time | 116 Days | 16 Days |
Enterprise Value | $179.56B | $13.04B |
Dividend Yield | 4.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.64, up 0.99% with bearish technical signals despite strong fundamentals. The company maintains exceptional profitability with 35.35% net margins and has beaten earnings estimates for three consecutive quarters. Recent news highlights pipeline developments including weight-loss drug advancements and a $4 billion licensing deal expansion.
While facing competitive pressure in obesity treatments, NVO's valuation remains attractive with a 9.66 P/E ratio. Analyst consensus is bullish with a $44.67 price target, representing 15.6% upside potential. Key risks include FDA regulatory delays and intensifying competition from Eli Lilly in the GLP-1 market.
Summit Therapeutics (SMMT) trades at $17.59, down 2.01% on the day, amid mixed earnings performance but strong analyst support with a consensus price target of $29.33. The stock shows a bullish technical signal from moving averages, with key support at $17 and resistance at $18. Recent news highlights a major $2 billion strategic investment from AstraZeneca and expanded clinical collaborations, boosting investor optimism despite current negative profitability metrics.
The outlook for SMMT is heavily driven by clinical progress and partnerships, offering significant upside if drug trials succeed, but carries high risk due to substantial losses, negative cash flow from operations, and reliance on positive trial outcomes. Investors should weigh the potential rewards against the company's current financial health and execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
